Resultados de la búsqueda 281-290 of 13203 for Leptospirosis, severe

1. Cirugía - Ensayos clínicos - Mayo Clinic

   The purpose of this study is to validate the use of a lymphatic imaging protocol to stage disease severity in patients with lymphedema and serve as a biomarker ...

2. Hematología - Ensayos clínicos - Mayo Clinic

   This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating participants with early-stage chronic lymphocytic leukemia or ...

3. Cirugía - Ensayos clínicos - Mayo Clinic

   The purpose of this study is to validate the use of a lymphatic imaging protocol to stage disease severity in patients with lymphedema and serve as a biomarker ...

4. Hematología - Ensayos clínicos - Mayo Clinic

   All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...

5. Hematología - Ensayos clínicos - Mayo Clinic

   This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

6. Cirugía - Ensayos clínicos - Mayo Clinic

   The purpose of this study is to validate the use of a lymphatic imaging protocol to stage disease severity in patients with lymphedema and serve as a biomarker ...

7. Cirugía - Ensayos clínicos - Mayo Clinic

   The purpose of this study is to validate the use of a lymphatic imaging protocol to stage disease severity in patients with lymphedema and serve as a biomarker ...

8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   Cell, Serum, and Buccal Bank for Patients with Chronic Myeloid Disorders and Acute Leukemia. Rochester, Minn. This study is being done to store blood, buccal ...

9. Oncología (médica) - Ensayos clínicos - Mayo Clinic

   The purpose of this study is to determine the safety and best dose of PRGN-3006 T Cells to treat relapsed/refractory Acute Myeloid Leukemia and High Risk ...

10. Hematología - Ensayos clínicos - Mayo Clinic

    All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...